Form 4 for EDIT Editas Medicine, Inc.
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-04 · accession 0001650664-25-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-05 | 2025-03-04 | EDIT | O'Neill Gilmore Neil | CEO, Dir | S - Sale | $1.71 | -16.6K | 295.5K | -5% | -$28.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | S | D | 16,632 | $1.71 | 295,474 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7125 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |